Rincon lithium project: US$2.5bn cost, 60,000tpa capacity, DLE technology and 2028 production timeline
Read More Pharma Industry News Ultragenyx Pharmaceutical faces shareholder litigation risks after Orbit study update triggers stock plunge Ultragenyx faces legal probe and investor scrutiny after a 25% stock drop tied to delayed Phase 3 Orbit study data for UX143. Learn what analysts expect next. byPallavi MadhirajuJuly 19, 2025